Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma

Current Opinion in Pediatrics

Volumn 22, Issue 3, 2010, Pages 290-295

  Nino, Gustavo ^a,b   Grunstein, Michael M ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Beta 2 adrenoreceptor agonists; Childhood asthma; Glucocorticosteroids; Inhaled corticosteroids; Long acting beta 2 agonists

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE PLUS SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NADOLOL; PLACEBO; PREDNISOLONE; SALMETEROL;

ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EARLY INTERVENTION; GROWTH DISORDER; HUMAN; LONG TERM CARE; MILD PERSISTENT ASTHMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WHEEZING;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; INFANT; NEBULIZERS AND VAPORIZERS; PHENOTYPE;

EID: 77952343739     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328337cb0c     Document Type: Review

References (56)

1. National Asthma Education and Prevention Program Coordinating Committee. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. Bethesda, Maryland, USA: National Heart, Lung, and Blood Institute; 2007.
2. Bush A, Menzies-Gow A. Phenotypic differences between pediatric and adult asthma. Proc Am Thorac Soc 2009;6:712-719.
3. Grunstein MM, Hakonarson H, Whelan R, et al. Rhinovirus elicits proasthmatic changes in airway responsiveness independently of viral infection. J Allergy Clin Immunol 2001; 108:997-1004.
4. Grunstein MM, Hakonarson H, Leiter J, et al. IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002; 282:L520-L528.
5. Grunstein MM, Veler H, Shan X, et al. Proasthmatic effects and mechanisms of action of the dust mite allergen, Der p 1, in airway smooth muscle. J Allergy Clin Immunol 2005; 116:94-101.
6. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32:1096-1110; Review.
7. Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009; 123:e519-e525.
8. Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med 2009; 360:329-338.
9. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362:1433-1438.
10. Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998-2005.
11. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997.
12. Murray CS, Woodcock A, Langley SJ, et al., IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754-762.
13. Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009;360:339-353.
14. Robertson CF, Price D, Henry R, et al. Short course montelukast for intermittent asthma in children: a randomised controlled trial. Am J Respir Crit Care Med 2007;175:323-329.
15. Bacharier LB, Phillips BR, Zeiger RS, et al., CARE Network. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122:1127-1135.
16. Bacharier LB, Guilbert TW, Zeiger RS, et al. Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol 2009; 123: 1077-1082; 1082.e1-1082.e5.
17. Busse WW, Pedersen S, Pauwels RA, et al. The inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167-1174.
18. Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343:1054-1063.
19. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high riskfor asthma. N Engl J Med 2006; 354:1985-1997.
20. Knuffman JE, Sorkness CA, Lemanske RF Jr, et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009; 123:411-416.
21. Beasley R, Pearce N, Crane J, Burgess C. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol 1999; 104:S18-S30.
22. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
23. Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65:39-43.
24. Gappa M, Zachgo W, von Berg A, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). Pediatr Pulmonol 2009; 44:1132-1142.
25. De Blic J, Ogorodova L, Klink R, et al. Salmeterol/fluticasone propionate versus double dose fluticasone propionate in children. Pediatr Allergy Immunol 2009; 20:763-771.
26. Ni Chroinin M, Lasserson TJ, Greenstone I, et al. Addition of long acting betaagonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009:CD007949.
27. Woolcock A, Lundback B, Ringdahl N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153:1481-1488.
28. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-1411.
29. Shapiro G, Lumry W, Wolfe J, et al. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161:527-534.
30. Kips J, O'Connor B, Inman M, et al. A long term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161:996-1001.
31. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-1397.
32. Papi A, Caramori G, Adcock IM, Barnes PJ. Rescue treatment in asthma. More than as-needed bronchodilation. Chest 2009; 135:1628-1633; Review.
33. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356:2040-2052.
34. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-136.
35. Papi A, Nicolini G, Baraldi E, et al. Regular vs prn nebulized treatment in wheeze preschool children. BEclomethasone and Salbutamol Treatment (BEST) for Children Study Group. Allergy 2009; 64:1463-1471.
36. Bel EH, Zwinderman AH, Timmers MC, et al. The protective effect of a beta2-agonist against excessive airway narrowing in response to bronchoconstrictor stimuli in asthma and chronic obstructive lung disease. Thorax 1991; 46:9-14.
37. Cheung D, Timmers MC, Zwinderman AH, et al. Long term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsive-ness in patients with mild asthma. N Engl J Med 1992; 327:1198-1203.
38. Wong AG, O'Shaughnessy AD, Walker CM, et al. Effects of long-acting and short-acting beta-agonists on methacholine dose-response curves in asthmatics. Eur Respir J 1997; 10:330-336.
39. Nino G, Hu A, Grunstein JS, Grunstein MM. Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensi-tization in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2009; 297:L746-L757.
40. Hu A, Nino G, Grunstein JS, et al. Prolonged heterologous beta2-adreno-ceptor desensitization promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1055-L1067.
41. van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005; 116:292-298.
42. Chapman RW, House A, Jones H, et al. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats. Eur J Pharmacol 2007; 571:215-221.
43. Hansen G, Jin S, Umetsu DT, Conti M. Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci U S A 2000; 97:6751-6756.
44. Kanehiro A, Ikemura T, Makela MJ, et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001; 163:173-184.
45. Sun JG, Deng YM, Wu X, et al. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma. Life Sci 2006; 79:2077-2085.
46. Tang HF, Song YH, Chen JC, et al. Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Respir Crit Care Med 2005; 171:823-828.
47. Nguyen LP, Lin R, Parra S, et al. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A 2009; 106:2435-2440.
48. Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008; 21:134-141.
49. Black JL, Oliver BG, Roth M. Molecular mechanisms of combination therapy with inhaled corticosteroids and long-acting beta-agonists. Chest 2009; 136:1095-1100; Review.
50. Kaur M, Chivers JE, Giembycz MA, et al. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 2008; 73:203-214.
51. Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274:1005-1010.
52. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19:182-191.
53. Mak JCW, Nishikawa M, Barnes PJ. Glucocorticosteroids increase β2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 12:L41-L46.
54. Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on down-regulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 1995; 96:99-106.
55. Cooper PR, Panettieri RA Jr. Steroids completely reverse albuterol-induced beta2-adrenergic receptor tolerance in human small airways. J Allergy Clin Immunol 2008; 122:734-740.
56. Nino G, Hu A, Grunstein JS, Grunstein MM. Mechanism of glucocorticoid protection of airway smooth muscle from proasthmatic effects of long-acting β2-adrenoceptor agonist exposure. J Allergy Clin Immunol (in press).